Based on studies showing clinical and molecular remissions in patients with acute myeloid leukemia and several case studies in IDH-mutant advanced glioma the small molecule Ivosidenib was recommended for certain patients (ESCAT IIA). This evidence concerns the gene IDH2 and glioma.